BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

Rhea-AI Summary

BioNTech SE (Nasdaq: BNTX) will announce its Q3 2021 financial results on November 9, 2021. A conference call and webcast for investors and analysts will be held at 8:00 a.m. ET (2:00 p.m. CET) the same day. Participants can access the presentation and audio via a provided link and will receive conference call details, including dial-in numbers and Conference ID. BioNTech continues to focus on immunotherapy development, having established partnerships with major pharmaceutical companies like Pfizer, Sanofi, and Bayer. Further information is available on their website.

Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter on Tuesday, November 9^th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021.

The slide presentation and audio of the webcast will be available via this link.

To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:

United States international: United States domestic (toll-free): Germany: Conference ID:

+1 646 741 3167 +1 877 870 9135 +49 (0) 692 2222 625 6835174

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.de.

BioNTech Contacts

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

FAQ

When will BioNTech announce its third quarter financial results?

BioNTech will announce its third quarter financial results on November 9, 2021.

What time is the BioNTech conference call for Q3 results?

The BioNTech conference call for Q3 results is scheduled for 8:00 a.m. ET on November 9, 2021.

How can I participate in the BioNTech Q3 conference call?

To participate in the BioNTech Q3 conference call, dial the provided numbers ten minutes before the start and use the Conference ID 6835174.

Will there be a replay of the BioNTech conference call?

Yes, a replay of the BioNTech conference call will be available shortly after the call and archived on the company’s website for 30 days.

What companies has BioNTech partnered with for its development?

BioNTech has partnered with major pharmaceutical companies including Pfizer, Sanofi, and Bayer for its development projects.